U.S. markets open in 2 hours 44 minutes
  • S&P Futures

    3,771.00
    -23.00 (-0.61%)
     
  • Dow Futures

    30,157.00
    -153.00 (-0.50%)
     
  • Nasdaq Futures

    11,550.25
    -73.50 (-0.63%)
     
  • Russell 2000 Futures

    1,755.80
    -12.20 (-0.69%)
     
  • Crude Oil

    87.66
    -0.10 (-0.11%)
     
  • Gold

    1,722.90
    +2.10 (+0.12%)
     
  • Silver

    20.67
    +0.13 (+0.64%)
     
  • EUR/USD

    0.9885
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    29.26
    +0.19 (+0.65%)
     
  • GBP/USD

    1.1256
    -0.0066 (-0.58%)
     
  • USD/JPY

    144.7580
    +0.1480 (+0.10%)
     
  • BTC-USD

    20,146.95
    +23.49 (+0.12%)
     
  • CMC Crypto 200

    457.68
    -0.73 (-0.16%)
     
  • FTSE 100

    7,014.75
    -37.87 (-0.54%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Nexgenrx Announces Declaration Of Dividend

·2 min read
NexgenRx Inc.

TORONTO, ON / ACCESSWIRE / September 23, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as at the close of business on October 3, 2022. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding. The common shares are listed and posted for trading on the TSX Venture Exchange under the symbol 'NXG'. The series 1 preferred shares are not listed or posted for trading on any stock exchange.

Ron Loucks, President and CEO of the Company, stated "we are very pleased to reward our shareholders with a second dividend this year, which is reflective of our ongoing positive performance and financial achievements."

About NexgenRx

NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software As a Service) Model.

NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The Company cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether the Company's strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company's proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in the Company's annual Management's Discussion and Analysis, as filed under the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. The Company undertakes no duty to update any of the forward-looking information to conform such information to actual results or to changes in the Company's expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801

Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393x803

SOURCE: NexgenRx Inc.



View source version on accesswire.com:
https://www.accesswire.com/717285/Nexgenrx-Announces-Declaration-Of-Dividend